CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1590714
This article is part of the Research TopicExploring Adverse Drug Reactions: Monitoring, Mechanism, Intervention, and ResolutionView all 8 articles
Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: A case report
Provisionally accepted- 1Shandong Provincial Third Hospital, Jinan, Shandong Province, China
- 2Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China
- 3Peking University Healthcare Lu Zhong Hospital, Zibo, Shandong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Immune checkpoint inhibitors (ICIs) have become an important part of malignant tumor therapy. However, some adverse reactions follow ICIs therapy. The incidence of immune-mediated colitis (IMC) has also increased. Here, the case of a 67-year-old male patient with stage IVB esophagogastric junction squamous cell carcinoma after chemotherapy, targeted therapy and immunotherapy is presented. This patient underwent treatment with six courses of protein-bound paclitaxel + cis-platinum+ sintilimab, followed by maintenance therapy with sintilimab alone. The patient developed intestinal obstruction, abdominal pain, hemorrhage of the lower digestive tract and other discomfort and was diagnosed with multiple jejunal ulcers via colonoscopy and pathological biopsy. The aims of presenting this case report are to improve clinicians' understanding of and ability to treat sintilimab-related adverse reactions and to more scientifically and rationally administer sintilimab for the treatment of malignant tumors.
Keywords: sintilimab1, immune checkpoint inhibitor2, hemorrhage of the digestive tract3, intestinal obstruction4, immune-related adverse event5
Received: 10 Mar 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Hao, Zhu, Guo, Lu, Zhang, Yang and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhonghua Song, Shandong Provincial Third Hospital, Jinan, Shandong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.